It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Revenues is expected to rise to about 6.2 B this year, although the value of Direct Expenses will most likely fall to about 283.5 M. Change time period & chart type. SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations. * indicates the important links in the menu. The Enterprise value factors in Market capitalization, cash, debt and other assets and liabilities. Compare with other stocks. Visit www.zacksdata.com to get our data and content for your mobile app or website. For advanced charting, view our full-featured. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Currency in USD ... Enterprise value/revenue 3: 5.99: Enterprise value/EBITDA 6: 11.31: Trading information. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. NYSE and AMEX data is at least 20 minutes delayed. Zacks Investment Research is releasing its prediction for ALXN based on the 1-3 month trading system that nearly triples the S&P 500. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - MDCA, VIE, CLGX, ALXN, TCF, SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations, INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, FFG, ALXN, NK, HLIX; Shareholders Are Encouraged to Contact the Firm, SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders About Its Ongoing Investigations. Alexion Pharm valuation ratios help investors to determine whether Alexion Pharm stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. In depth view into Alexion Pharmaceuticals Enterprise Value including historical data from 1996, charts, stats and industry comps. Find out all the key statistics for Alexion Pharmaceuticals, Inc. (ALXN), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. It's what it would really cost you to buy the company. Investors Jennifer Zibuda, IR@portola.com. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. See rankings and related performance below. Learn to demonstrate project value to the company through metrics presentations, 1:1 reviews, etc. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. 2) 100.7% Change in EBITDA Per Share. Hey investors, ALEXION PHARMACEUTICAL gives a bullish signal on a sell volume and we can see a hammer bear candle. Compare with other stocks. EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Equity return is now at value 5.40, with 3.40 for asset returns. It’s an Opportunity for Investors. These returns cover a period from January 1, 1988 through January 4, 2021. As a percentage, the higher the Earnings Yield, the better value the share. To learn more, click here. In the TIMEFRAME 1 Min we see a bullish continuity, it goes back to erase the crisis at the start of the session. Alexion Pharmaceuticals | ALXN - Enterprise Value - actual data and historical chart - was last updated on January of 2021 according to the latest Annual and Quarterly Financial Statements ALEXION PHARMACEUTICAL will try to test the median may even break it, if buyers make a strong comeback. That would give Alexion, whose share price has quadrupled since the end of 2009, an enterprise value of at least $28 billion, or 61 times its EBITDA from the past 12 months. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. We have many different tools that can be utilized to determine how healthy Alexion Pharm is … The total capital return value is set at 20.17, while invested capital returns managed to touch 4.28. Source: Ycharts. Career opportunities are published only through Alexion’s official communication channels. Alexion Pharmaceuticals stock hasn’t moved much this year. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. ... Teilt man den Enterprise Value durch den Umsatz so erhält man eine wichtige Kennzahl zur Einschätzung der Bewertung von schnell wachsenden aber noch defizitären Technologieunternehmen. Based on Alexion Pharmaceuticals Inc. (ALXN), the company’s capital structure generated 24.38 points at debt to equity in total, while total debt to capital is 19.60. Start a 14-day free trial to Morningstar Premium to unlock our price to fair value estimate. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Open Menu. ... We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The company's current value of Operating Income is estimated at 2.65 Billion. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. View and export this data going back to 1996. We use cookies to understand how you use our site and to improve your experience. The Alexion Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 16.58.The shares are currently trading at $153.53.. 4) -15.6% Change in Debt Load Alexion Pharmaceuticals Inc. [ALXN] has a Price to Book Ratio of 2.12, a Price to Cash Flow Ratio of 11.66 and P/E Ratio of 9.23. Enterprise Value: Alexion Partners works with C-level business executives to enhance enterprise value, across a wide range of industries and functions. Learn the life cycle of change implementation in front end enterprise systems (gather business requirements, test, and train) Work at the forefront of an accelerated digital environment in … Alexion Pharmaceuticals, Inc. (ALXN) Quote Overview, Alexion Pharmaceuticals, Inc. (ALXN) Fundamental Charts Enterprise Value, Immunovant (IMVT) Gains on a Potential Buyout by Roivant. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ALXN has a market cap or net worth of $33.67 billion. EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings. Real time prices by BATS. It's packed with all of the company's key stats and salient decision making information. Alexion Pharmaceuticals, Inc. (ALXN) Enterprise Value and Market Cap. Read full definition. Alexion Pharmaceuticals Enterprise Value Calculation. Alexion Pharmaceuticals, Inc. (ALXN) NasdaqGS - NasdaqGS Real Time Price. The scores are based on the trading styles of Value, Growth, and Momentum. This includes personalizing content and advertising. Career opportunities are published only through Alexion’s official communication channels. Advertisement ... Morningstar Enterprise Components ... Alexion Pharmaceuticals Inc ALXN Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Equity return is now at value 5.40, with 3.40 for asset returns. The fund's Alexion Pharmaceuticals Inc. (ALXN) position was closed. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market, Alexion Pharmaceuticals Inc. stock falls Thursday, underperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Alexion Pharmaceuticals's Enterprise Value for the fiscal year that ended in … What is the current enterprise value of Alexion Pharmaceuticals? Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? Zacks Ranks stocks can, and often do, change throughout the month. Alexion Pharmaceuticals has become aware of scams from individuals, organizations, and Internet sites claiming to represent Alexion in recruitment activities in return for disclosing financial information. In this new role, Mr. Qadeer will be responsible for shaping the company’s diversity, inclusion and belonging (DI&B) strategy, building relationships with key leaders, communities, and organizations to … Alexion Pharmaceuticals, Inc. (ALXN) NasdaqGS - NasdaqGS Real Time Price. Learn more about Zacks Equity Research reports. The monthly returns are then compounded to arrive at the annual return. Graphic visualization charts. Alexion. If you do not, click Cancel. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The company's Enterprise Value represents the value of a company's ongoing business. An error occurred. As of today, Alexion Pharmaceuticals's enterprise value is $33,291 Mil.Alexion Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $1,003 Mil.Therefore, Alexion Pharmaceuticals's EV-to-EBITDA for today is 33.19. Delayed quotes by Sungard. The enterprise value is $34.14 billion. It gives you a total value of the stock (including its cash and debt), which makes it easier to compare different stocks. The total capital return value is set at 20.17, while invested capital returns managed to touch 4.28. The company has a market cap of $5.37 billion and an enterprise value … The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. 7.8% stock price increase driven by factors: 1) -59.9% EV/EBITDA Ratio contraction. The portfolio was impacted by -0.91%. Notice that in 2003, 2004, and 2005, Alexion had an enterprise value between $200 million and $500 million. Alexion Pharmaceuticals's stock price increased from $97.36 at the end of 2018 to $104.98 currently, a moderate increase of 7.8%. NASDAQ data is at least 15 minutes delayed. These metrics all suggest that Alexion Pharmaceuticals Inc. is more likely to generate a positive ROI. ... Alexion Partners is an International Management Consulting Services firm headquartered in Berlin, Germany. Alexion Pharmaceuticals Operating Income is quite stable at the moment as compared to the past year. Currency in USD ... Enterprise value/revenue 3: 5.99: Enterprise value/EBITDA 6: 11.31: Trading information. Start a 14-day free trial to Morningstar Premium to unlock our price to fair value estimate. Alexion Pharmaceuticals has become aware of scams from individuals, organizations, and Internet sites claiming to represent Alexion in recruitment activities in return for disclosing financial information. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. ALXN vs. BMRN: Which Stock Is the Better Value Option. STOCK ALERT: Halper Sadeh LLP Investigates MGLN, CATM, EGOV, ALXN; Shareholders Are Encouraged to Contact the Firm, SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations, Crispr Therapeutics Hits 80-Plus Relative Strength Rating Benchmark, INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CATM, RNET, MDCA, SPWH; Shareholders are Encouraged to Contact the Firm. Alexion Pharmaceuticals Enterprise Value Calculation. ZacksTrade and Zacks.com are separate companies. 6 months, 1 - 10 years. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Learn to demonstrate project value to the company through metrics presentations, 1:1 reviews, etc. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. Enterprise Value is a widely used stock evaluation measure. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) went down by -3.53% from its latest closing price compared to the recent 1-year high of $121.50. Find out all the key statistics for Alexion Pharmaceuticals, Inc. (ALXN), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Source: Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. Tangible Asset Value is expected to rise to about 10.8 B this year, although Enterprise Value will most likely fall to about 33.4 B. Enterprise Value Definition. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. The Enterprise Value to Sales for this firm is now 4.65, and its Total Debt to Enterprise Value stands at 0.11.